58% of buyers now start their research in ChatGPT or Gemini, not Google. Most startups aren't showing up there yet.

The ones that are get cited by the AI tools their buyers, investors, and future hires already use. And they convert at 3×.

Download the free AEO Playbook for Startups from HubSpot and get the exact steps to start showing up. Five minutes to read.

Get the free playbook

👋 Hi, it’s Rohit Malhotra and welcome to the FREE edition of Partner Growth Newsletter, my weekly newsletter doing deep dives into the fastest-growing startups and S1 briefs. Subscribe to join readers who get Partner Growth delivered to their inbox every Wednesday morning.

If you’re new, not yet a subscriber, or just plain missed it, here are some of our recent editions.

_{Interested in sponsoring these emails? See our partnership options here.}

Subscribe to the Life Self Mastery podcast, which guides you on getting funding and allowing your business to grow rocketship. 

Previous guests include Guy Kawasaki, Brad Feld, James Clear, Nick Huber, Shu Nyatta and 350+ incredible guests.

Anthropic acquiring Coefficient Bio isn't a healthcare play. It's a structural move from a company that watched every major AI lab race toward life sciences and decided it couldn't keep selling general intelligence without owning domain expertise in the industry where it matters most.

On the surface: the Claude maker buying a six person stealth startup nobody outside biotech circles had heard of. A talent acquisition. A capability bet. The kind of deal that gets filed under "acqui-hire" and forgotten by Friday.

Look closer, and the logic gets sharper.

Coefficient wasn't some half-baked demo. It was founded by operators who had already lived inside the problem. A chief business officer who built Nvidia partnerships at a protein engineering company. A principal scientist who spent years at Biogen. A Roivant Sciences principal who understood how drugs actually get commercialized. Three co-founders who collectively covered discovery, development, and deal-making.

Anthropic, meanwhile, had Claude for Healthcare. It had Claude for Life Sciences. It had the models, the enterprise relationships, the regulatory positioning. What it didn't have was a team that could wire those models directly into the biology.

So instead of spending years recruiting one scientist at a time, Anthropic bought the team that already existed. For $400 million in stock. For a company founded in 2025 with six employees.

The deal hasn't been officially confirmed. But the signal it sends is louder than the price tag. AI in drug discovery doesn't work without people who understand both the models and the molecules. And Anthropic just made sure it has them.

Coefficient Bio didn't start as a $400 million acquisition target with a team of six and a stealth profile that most of the industry never even noticed. It started as a thesis. Drug discovery was too slow. Biological research was drowning in data that AI models couldn't meaningfully interpret. And someone needed to bridge the gap between foundation models and actual molecules before the next wave of AI investment in healthcare became another cycle of expensive disappointment.

Aris Theologis didn't build Coefficient inside an AI hype cycle chasing chatbot wrappers and prompt engineering toolkits. He built it around a core conviction he had developed across years at Paragon Biosciences and Evozyne: that the real bottleneck in computational biology wasn't compute power or model architecture. It was the translation layer. The space between what a large language model could process and what a scientist actually needed to know to advance a drug candidate. Coefficient was the company built to collapse that distance.

The timing looked niche. It was actually prescient.

While the rest of the AI industry chased enterprise productivity tools and coding assistants, Coefficient was assembling a founding team that covered the full stack of drug development. Nathan Frey brought principal scientist experience from Biogen, one of the world's largest biotech companies, with deep expertise in how computational methods actually intersect with therapeutic pipelines. Joyce Hong brought nearly five years at Roivant Sciences, where she had operated at the intersection of investment, commercialization, and portfolio strategy across multiple drug programs. Theologis himself had built and expanded an Nvidia partnership at Evozyne, proving he understood how to wire AI infrastructure into biology at an operational level.

These weren't academics writing white papers about theoretical applications. These were operators who had watched AI tools fail inside real pharmaceutical workflows and knew exactly where the integration points needed to be.

The company was founded in 2025. Based in New York. Six employees. No public product announcements. No press tours. No splashy conference demos. Just a small team building quietly in stealth while every major AI lab in the world was publicly announcing its healthcare ambitions without the domain talent to execute on them.

By the time Anthropic came calling in early 2026, Coefficient had something that couldn't be replicated with a recruiting budget and a job board: a founding team that understood both the models and the medicine, already aligned, already building, and already thinking about the problem the way Anthropic needed someone to think about it.

Here's what makes the structure interesting: Anthropic is acquiring a company with six employees, no public product, and zero revenue visibility, for $400 million in stock. The question isn't whether the price looks inflated on a per-head basis. The question is whether Anthropic had any faster path to what it actually needed.

The timeline tells the story.

2025: Aris Theologis co-founds Coefficient Bio in New York with Nathan Frey and Joyce Hong. The team builds in stealth while every major AI company announces healthcare ambitions without the domain bench to deliver on them.

October 2025: Anthropic launches Claude for Life Sciences, covering preclinical R&D through regulatory affairs. The product positioning is strong. The biology talent behind it is thin.

January 2026: Claude for Healthcare goes live. Eric Kauderer-Abrams, Anthropic's head of biology and life sciences, publicly calls healthcare one of the company's largest strategic bets. The gap between ambition and execution capacity becomes harder to ignore.

April 2026: Reports surface that Anthropic is acquiring Coefficient for $400 million in stock. The deal has not been officially confirmed. The signal is already clear.

But here's what Anthropic actually bought.

The team: A CEO who built Nvidia partnerships inside a protein engineering company. A CTO who was a principal scientist at Biogen. A co-founder who spent five years evaluating and commercializing drug programs at Roivant Sciences. Three people who collectively understand discovery, development, and deal-making.

The domain translation layer: Anthropic had models. It had enterprise healthcare relationships. It did not have operators who could wire foundation models into actual drug discovery workflows at the integration points where AI tools historically fail.

The speed: Recruiting this caliber of interdisciplinary talent one hire at a time takes years. Acquiring a team that is already aligned, already building, and already operating with shared conviction compresses that timeline to a single transaction.

To understand why Anthropic acquired Coefficient Bio, you need to understand what Anthropic actually is. Not just a frontier AI lab. Not just a safety research company with a commercial product. A foundation model company whose entire strategic position depends on proving that general intelligence can be applied to the hardest, highest-stakes domains in the world. And the gap between where Anthropic was and where it needed to be was exactly the biology expertise Coefficient had already assembled.

Coefficient did one thing obsessively well: understand where AI models break down inside actual drug discovery workflows. While other AI companies chased healthcare partnerships through marketing announcements and white papers, Coefficient was building at the translation layer where foundation models meet molecular biology, the exact point where most AI healthcare initiatives quietly stall and die. Anthropic's life sciences future required exactly that expertise. It just didn't have it yet.

Here's the strategic advantage: domain credibility compounds over time. The relationships, institutional knowledge, and scientific trust accumulating inside pharmaceutical and biotech organizations now will define who controls the AI life sciences market a decade from now. Coefficient's founders had already spent careers building that credibility at Biogen, Roivant, Evozyne, and Paragon Biosciences.

The real world difference wasn't subtle. Pharma companies don't just need better models. They need AI systems that understand assay data, target validation, clinical endpoints, and regulatory pathways well enough to accelerate decisions that cost hundreds of millions of dollars if they go wrong. That isn't a chatbot summarizing research papers. That is a full stack domain integration commitment. Coefficient wasn't just a biotech startup. It was a team with the scientific depth and industry trust oriented around exactly that requirement.

And this mattered more as AI healthcare moved from demo to deployment.

Anthropic saw all of it. The talent gap. The credibility gap. The strategic position in a market where whoever earns the trust of drug developers first owns the infrastructure on which the next generation of computational biology gets built.

Coefficient wasn't building toward an independent IPO. It was building toward combination.

The Anthropic deal exposes a quiet truth about AI biotech startups: building world-class domain expertise without a foundation model behind you is an acquisition target, not a permanently independent business.

Most AI healthcare startups are fighting over the same ground: better model fine-tuning, cleaner clinical data pipelines, faster literature summarization. It's the most obvious place to compete, which makes it the most crowded. You're racing against every frontier lab that decides life sciences is its next vertical, competing for pharma partnerships against companies with thousand-person research teams, and hoping your wrapper stays differentiated before Anthropic or OpenAI or Google decides your niche is their next default offering.

Coefficient went one level deeper: the translation layer between foundation models and actual biology. Founders who had operated inside Biogen, Roivant, and Evozyne. People who understood not just what models could do, but where they failed inside real therapeutic pipelines. They didn't just build AI tools. They built domain credibility that couldn't be replicated with a recruiting budget alone.

That positioning made them acquirable in under a year. $400 million for six people. Not because of revenue. Because Anthropic needed what couldn't be built fast enough internally: scientific credibility, pharmaceutical fluency, and a team already wired to think about the problem correctly.

The Anthropic deal will get filed under AI healthcare M&A. It belongs in a different category.

This isn't a large company absorbing a smaller one to fill a headcount gap. It's the moment a frontier AI lab formally acknowledged that foundation models alone aren't enough to win life sciences. The domain expertise, the scientific credibility, the ability to operate at the intersection of biology and intelligence, that is the moat. And the race to lock it up is already underway.

The teams that built domain depth early are getting absorbed into the platforms that need them. The companies that waited are now recruiting one scientist at a time against a shrinking talent pool and a more expensive competitive landscape.

For the broader AI healthcare industry, the signal is unambiguous. Pharma companies need more than better models. They need AI systems built by people who understand the science, the regulatory complexity, and the operational reality of drug development. The gap between what AI can theoretically do in biology and what it can actually deliver in a therapeutic pipeline is about to get significantly smaller, significantly faster, and significantly more concentrated inside the platforms that invested in domain talent first.

Anthropic didn't acquire Coefficient because AI healthcare won. It acquired Coefficient because it couldn't afford to find out what losing the biology layer looked like.

The talent layer just changed hands. Everything built on top of it changes next.

Here is my interview with Oliver Manojlovic, CRO at Dash0, the agentic observability platform that just acquired Lumigo and is supporting 600+ customers globally.

If you enjoyed our analysis, we’d very much appreciate you sharing with a friend.

Here are the options I have for us to work together. If any of them are interesting to you - hit me up!

And that’s it from me. See you next week.

What do you think about my bi-weekly Newsletter? Love it | Okay-ish | Stop it